BidaskClub downgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a hold rating to a sell rating in a research note released on Wednesday.

Other equities analysts also recently issued research reports about the stock. Cantor Fitzgerald set a $8.00 price target on shares of Catalyst Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, November 8th. Oppenheimer set a $6.00 price target on shares of Catalyst Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, October 16th. HC Wainwright set a $6.00 price target on shares of Catalyst Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, August 22nd. Finally, Zacks Investment Research raised shares of Catalyst Pharmaceuticals from a hold rating to a buy rating and set a $3.25 price target on the stock in a research note on Monday, August 13th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $5.65.

NASDAQ:CPRX opened at $2.39 on Wednesday. Catalyst Pharmaceuticals has a fifty-two week low of $2.18 and a fifty-two week high of $4.29.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.08). On average, research analysts forecast that Catalyst Pharmaceuticals will post -0.3 earnings per share for the current year.

A number of large investors have recently bought and sold shares of CPRX. Rhumbline Advisers raised its stake in shares of Catalyst Pharmaceuticals by 34.7% in the 2nd quarter. Rhumbline Advisers now owns 90,725 shares of the biopharmaceutical company’s stock valued at $283,000 after acquiring an additional 23,383 shares during the period. Millennium Management LLC raised its stake in shares of Catalyst Pharmaceuticals by 16.5% in the 2nd quarter. Millennium Management LLC now owns 1,610,176 shares of the biopharmaceutical company’s stock valued at $5,024,000 after acquiring an additional 227,918 shares during the period. GSA Capital Partners LLP raised its stake in shares of Catalyst Pharmaceuticals by 295.7% in the 2nd quarter. GSA Capital Partners LLP now owns 380,605 shares of the biopharmaceutical company’s stock valued at $1,187,000 after acquiring an additional 284,409 shares during the period. Schwab Charles Investment Management Inc. raised its stake in shares of Catalyst Pharmaceuticals by 12.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 208,404 shares of the biopharmaceutical company’s stock valued at $651,000 after acquiring an additional 23,500 shares during the period. Finally, Lido Advisors LLC raised its stake in shares of Catalyst Pharmaceuticals by 46.5% in the 2nd quarter. Lido Advisors LLC now owns 87,506 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 27,766 shares during the period. 49.61% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Featured Article: How To Calculate Debt-to-Equity Ratio

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.